<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NITAZOXANIDE</span><br/>(nit-a-zox'-a-nide)<br/><span class="topboxtradename">Alinia<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiprotozoal</span><br/><b>Prototype: </b>Metronidazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg/5 mL powder for reconstitution; 500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antiprotozoal activity believed to be due to interference with an essential enzyme needed for anaerobic energy metabolism
         in protozoa. Interference with the enzyme may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits growth of sporozoites and oocysts of <i>Cryptosporidium parvum</i> and trophozoites of <i>Giardia lamblia</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of diarrhea caused by <i>Cryptosporidium parvum</i> and <i>Giardia lamblia</i>.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Prior hypersensitivity to nitazoxanide.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic and biliary disease, renal disease and combined renal and hepatic disease; safety and efficacy in children 11 y have not been studied; pregnancy (category B); lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diarrhea</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>1247 mo,</i> 100 mg (5 mL) q12 h <small>x</small> 3 d; <i>411 y,</i> 200 mg (10 mL) q12 h <small>x</small> 3 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Prepare suspension as follows: Tap bottle until powder loosens. Draw up 48 mL of water, add half to bottle, shake to suspend
            powder, then add remaining 24 mL of water and shake vigorously.
         </li>
<li>Give required dose (5 or 10 mL) with food.</li>
<li>Keep container tightly closed, and shake well before each administration.</li>
<li>Suspension may be stored for 7 d at 15°30° C (59°86° F), after which any unused portion must
            be discarded.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Abdominal pain, diarrhea, vomiting. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions reported. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 14 h. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide). Tizoxanide then undergoes conjugation, primarily
      by glucuronidation. <span class="typehead">Elimination:</span> Excreted in urine and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: No watery stools and <img src="../images/special/lesserorequal.gif"/>2 soft stools
            with no hematochezia within the past 24 h or no symptoms and no unformed stools within the past 48 h.
         </li>
<li>Monitor closely patients with preexisting hepatic or biliary disease for adverse reactions.</li>
<li>Assess appetite, level of abdominal discomfort and extent of bloating.</li>
<li>Assess frequency and quantity of diarrhea and monitor total hydration status.</li>
<li>Weigh daily to aid in assessment of possible fluid loss from diarrhea.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Note that 5 mL of the oral suspension contains approximately 1.5 g of sucrose.</li>
<li>Report either no improvement in or worsening of diarrhea and abdominal discomfort.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>